BC21 blocks the clonogenic activity of colon cancer cells, down-regulates c-Myc and cyclin-D1 expression, and represents a new potential anticancer agent that targets TCF4/beta-catenin interaction [16]. The gene discussed is TCF4; the disease is colonic neoplasm.